In the era of blockbuster obesity drugs, a personalized approach could boost outcomes

The pharmaceutical industry has seen a wave of interest in weight loss drugs like Ozempic and Wegovy. However, obesity is complex, and a personalized approach is key to finding what works best for each individualized patient. In a recent article in PharmaVoice, our CEO shares how phenotyping is bringing precision medicine to the obesity space and how pharmaceutical companies can benefit from and play a dynamic role in this movement. 

“Like a lot of different areas of medicine, we’re finding that people are different — big surprise — and as a result, they respond differently to different interventions,” Bagnall said. “And 10 years of NIH-sponsored research into quantitative measures of obesity determined that 85% of patients have fundamentally four different subtypes or phenotypes of obesity.”

After running reams of data through machine learning analysis and artificial intelligence bioinformatics systems, Phenomix developed a test that could fit into a normal doctor visit and determine which of the four types of obesity a patient has, making certain treatments more likely to help.

Read the full article here.

HCP Inquiry Form

Please provide your first and last name. Required

Please provide your title. Required

Please provide your email address Required

Please type the letters and numbers shown in the image. Click the image to see another captcha.

Submit